| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
153,997 |
125,339 |
$5.21M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
48,824 |
42,551 |
$2.07M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
65,096 |
59,731 |
$870K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
11,760 |
11,570 |
$830K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
11,350 |
11,098 |
$827K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
57,107 |
26,710 |
$765K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
10,766 |
10,523 |
$739K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,187 |
13,298 |
$729K |
| S8301 |
Infection control supplies, not otherwise specified |
81,611 |
63,488 |
$560K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
7,137 |
6,815 |
$491K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
44,460 |
20,645 |
$442K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
56,802 |
48,801 |
$357K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
24,628 |
22,601 |
$303K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
10,471 |
9,980 |
$227K |
| 99000 |
|
15,826 |
13,886 |
$157K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,736 |
2,692 |
$148K |
| 99429 |
|
4,139 |
4,057 |
$125K |
| 99381 |
|
1,650 |
1,613 |
$123K |
| 87807 |
|
9,028 |
8,354 |
$96K |
| 99050 |
|
5,955 |
5,752 |
$84K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
1,126 |
1,068 |
$77K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,593 |
2,471 |
$76K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
2,592 |
2,440 |
$75K |
| 86328 |
|
845 |
814 |
$74K |
| 90461 |
|
13,864 |
11,319 |
$65K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
7,227 |
5,015 |
$52K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
4,771 |
4,367 |
$52K |
| 0071A |
|
1,100 |
1,076 |
$42K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,061 |
2,877 |
$39K |
| 0072A |
|
808 |
805 |
$32K |
| 0001A |
|
905 |
889 |
$27K |
| 0002A |
|
738 |
729 |
$25K |
| 94010 |
|
782 |
704 |
$18K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
239 |
234 |
$18K |
| 99383 |
|
223 |
223 |
$18K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
13,907 |
12,985 |
$17K |
| CP002 |
|
1,706 |
1,333 |
$16K |
| 81002 |
|
5,813 |
5,314 |
$16K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
372 |
359 |
$15K |
| 99382 |
|
177 |
176 |
$14K |
| 94016 |
|
780 |
702 |
$14K |
| 96160 |
|
5,870 |
5,727 |
$9K |
| 0003A |
|
236 |
230 |
$9K |
| 87428 |
|
241 |
229 |
$9K |
| 92567 |
|
720 |
693 |
$9K |
| 99384 |
|
53 |
53 |
$5K |
| 0011A |
|
210 |
204 |
$4K |
| 99051 |
|
336 |
332 |
$3K |
| 0012A |
|
139 |
137 |
$3K |
| 84030 |
|
717 |
688 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
13,912 |
13,049 |
$2K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
760 |
746 |
$2K |
| 0073A |
|
40 |
40 |
$2K |
| 86580 |
|
230 |
224 |
$1K |
| 0081A |
|
35 |
34 |
$1K |
| 81025 |
|
166 |
158 |
$1K |
| 69210 |
|
41 |
40 |
$1K |
| 97802 |
|
2,132 |
1,513 |
$1K |
| 97169 |
|
58 |
57 |
$1K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
12 |
12 |
$965.64 |
| 97170 |
|
38 |
36 |
$900.00 |
| 90651 |
|
2,303 |
2,285 |
$518.64 |
| 96380 |
|
13 |
13 |
$212.25 |
| 90670 |
|
4,893 |
4,852 |
$203.15 |
| 90620 |
|
1,241 |
1,235 |
$193.49 |
| 90680 |
|
3,859 |
3,831 |
$181.90 |
| 90619 |
|
1,214 |
1,209 |
$170.11 |
| 92587 |
|
17 |
16 |
$119.84 |
| 90686 |
|
4,982 |
4,942 |
$116.50 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
103 |
98 |
$5.28 |
| 90671 |
|
1,463 |
1,457 |
$1.52 |
| 90744 |
|
1,131 |
1,121 |
$0.48 |
| 90734 |
|
1,689 |
1,676 |
$0.31 |
| 90633 |
|
3,479 |
3,449 |
$0.30 |
| 90710 |
|
2,935 |
2,913 |
$0.19 |
| 90715 |
|
1,790 |
1,778 |
$0.17 |
| 90648 |
|
435 |
435 |
$0.12 |
| 90696 |
|
1,374 |
1,362 |
$0.08 |
| 90716 |
|
221 |
221 |
$0.03 |
| 90707 |
|
190 |
189 |
$0.03 |
| 91307 |
|
1,994 |
1,848 |
$0.00 |
| 90698 |
|
2,927 |
2,904 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
33 |
28 |
$0.00 |
| 90697 |
|
2,485 |
2,469 |
$0.00 |
| 90381 |
|
12 |
12 |
$0.00 |
| 91301 |
|
374 |
358 |
$0.00 |
| 91300 |
|
2,014 |
1,823 |
$0.00 |
| 91308 |
|
28 |
26 |
$0.00 |
| 90700 |
|
594 |
590 |
$0.00 |
| 90713 |
|
12 |
12 |
$0.00 |
| 90658 |
|
12 |
12 |
$0.00 |